Prof.Dr. ALİ OSMAY GÜRE

Kişisel Bilgiler

İş Telefonu: +90 216 500 4130
E-posta: ali.gure@acibadem.edu.tr
Web: https://avesis.acibadem.edu.tr/ali.gure

Uluslararası Araştırmacı ID'leri
ScholarID: YCCIgOoAAAAJ
ORCID: 0000-0002-4064-8608

Eğitim Bilgileri

Doktora, Cornell University, Immunoloji, Amerika Birleşik Devletleri 1988 - 1995
Lisans, Ankara Üniversitesi, Tıp Fakültesi, Tıp Pr., Türkiye 1981 - 1988

Yabancı Diller

Almanca, B1 Orta
İngilizce, C1 İleri

Araştırma Alanları

Tıbbi Biyoloji, İmmünoloji, Genomiks, Kanser Moleküler Biyolojisi

Akademik Unvanlar / Görevler

Doç.Dr., İhsan Doğramacı Bilkent Üniversitesi, Fen Fakültesi, Moleküler Biyoloji Ve Genetik Bölümü, 2006 - 2020
Yrd.Doç.Dr., Cornell University, 2006 - 2010
Yrd.Doç.Dr., Ludwig Institute For Cancer Research At Mskcc, Cancer Serology, 2000 - 2006
Araştırma Görevlisi, Memorial Sloan Kettering Cancer Center, Cancer Serology, 1995 - 2006

Akademik İdari Deneyim

Anabilim/Bilim Dalı Başkanı, Acıbadem Mehmet Ali Aydınlar Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2020 - Devam Ediyor

Verdiği Dersler

Cell Biology - Cell Theory, Yüksek Lisans, 2021 - 2022
Genomics, Lisans, 2020 - 2021
DNA Damage and Repair Mechanisms (MBG485), Lisans, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2010 - 2011, 2009 - 2010

Biology I (MBG101), Lisans, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2010 - 2011, 2009 - 2010
Genomics (MBG418), Lisans, 2013 - 2014, 2012 - 2013
Molecular Biology of the Cell I (MBG3010, Lisans, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2010 - 2011, 2009 - 2010, 2008 - 2009, 2007 - 2008
Principles of Gene Expression (MBG608), Doktora, 2011 - 2012, 2010 - 2011
Recent Advances in Molecular Biology (MBG615), Doktora, 2009 - 2010, 2008 - 2009, 2007 - 2008
Introduction to Modern Biology, Lisans, 2008 - 2009, 2007 - 2008, 2006 - 2007
Molecular and Cellular Immunology (MBG602), Doktora, 2006 - 2007
Immunology (MBG470), Lisans, 2006 - 2007

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

I. **Transcriptomic Analysis of Hepatitis B Infected Liver for Prediction of Hepatocellular Carcinoma**
Karaoglu D. A., ÜNER M., Simsek C., GÜRE A. O., DEMİRKOL CANLI S.
BIOLOGY-BASEL, cilt.12, sa.2, 2023 (SCI-Expanded)

II. **DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study**
Faleiro I., Roberto V. P., DEMİRKOL CANLI S., Fraunhoffer N. A., Iovanna J., GÜRE A. O., Link W., Castelo-Branco P.
CANCERS, cilt.13, sa.24, 2021 (SCI-Expanded)

III. **Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma**
Akgün H., Metintaş S., Ak G., Demirkol Canlı S., Güre A. O., Metintaş M.
ARCHIVES OF MEDICAL SCIENCE, cilt.1, ss.1-10, 2021 (SCI-Expanded)

IV. **Steroid receptor RNA activator gene footprint in the progression and drug resistance of colorectal cancer through oxidative phosphorylation pathway**
Mahdevar M., Vatandoost J., Forootan F. S., Kiani-Esfahani A., Esmaeili M., Peymani M., Tavakkoli H., GÜRE A. O., Esfahani M. H. N., Ghaedi K.
LIFE SCIENCES, cilt.285, 2021 (SCI-Expanded)

V. **Hypothetical molecular interconnection between type 2 diabetes and dyslexia**
Bulbul T., Baharlooie M., Safaeinejad Z., GÜRE A. O., Ghaedi K.
BMC NEUROSCIENCE, cilt.22, sa.1, 2021 (SCI-Expanded)

VI. **Epithelial-to-Mesenchymal Transition Is Not a Major Modulating Factor in the Cytotoxic Response to Natural Products in Cancer Cell Lines**
Kucukkaraduman B., Cicek E. G., Akbar M. W., DEMİRKOL CANLI S., VURAL B., GÜRE A. O.
MOLECULES, cilt.26, sa.19, 2021 (SCI-Expanded)

VII. **Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide**
TÜRK S., TÜRK C., Akbar M. W., Kucukkaraduman B., Isbilen M., DEMİRKOL CANLI S., MALKAN Ü. Y., Okay M., UÇAR G., SAYINALP N., et al.
PLOS ONE, cilt.15, sa.11, 2020 (SCI-Expanded)

VIII. **Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development**
Azizian-Farsani F., Abedpoor N., Hasan Sheikhha M., Gure A. O., Nasr-Esfahani M. H., Ghaedi K.
FRONTIERS IN ONCOLOGY, cilt.10, 2020 (SCI-Expanded)

IX. **Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway**
Demirkol Canli S., Seza E. G., SHERAJ I., Gomceli I., Turhan N., Carberry S., Prehn J. H. M., GÜRE A. O., BANERJEE S.
CARCINOGENESIS, cilt.41, sa.9, ss.1219-1228, 2020 (SCI-Expanded)

X. **Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells**
Kucukkaraduman B., TÜRK C., Fallacara A. L., Isbilen M., Senses K. M., Ayyildiz Z. O., Akbar M. W., Lotem M., Botta M.,

GÜRE A. O.
ACS MEDICINAL CHEMISTRY LETTERS, cilt.11, sa.5, ss.928-932, 2020 (SCI-Expanded)

XI. **Intracellular functions of RNA-binding protein, Musashi1, in stem and cancer cells**
Forouzanfar M., Lachinani L., Dormiani K., Nasr-Esfahani M. H., Gure A. O., Ghaedi K.
STEM CELL RESEARCH & THERAPY, cilt.11, sa.1, 2020 (SCI-Expanded)

XII. **A novel 20-gene prognostic score in pancreatic adenocarcinoma**
DEMİRKOL CANLI S., Dedeoglu E., Akbar M. W., Kucukkaraduman B., Isbilen M., Erdogan O. S., KILIÇ ERCİYAS S., YAZICI H., VURAL B., GÜRE A. O.
PLOS ONE, cilt.15, sa.4, 2020 (SCI-Expanded)

XIII. **Mechanistic Pathways of Malignancy in Breast Cancer Stem Cells**
Yousefnia S., Forootan F. S., Forootan S. S., Esfahani M. H. N., Gure A. O., Ghaedi K.
FRONTIERS IN ONCOLOGY, cilt.10, 2020 (SCI-Expanded)

XIV. **The effect of Maras powder and smoking on the microRNA deregulation of oral mucosa**
Tas B., Gure A. O.
JOURNAL OF APPLIED ORAL SCIENCE, cilt.28, 2020 (SCI-Expanded)

XV. **A Stemness and EMT Based Gene Expression Signature Identifies Phenotypic Plasticity and is A Predictive but Not Prognostic Biomarker for Breast Cancer**
Akbar M. W., Isbilen M., BELDER N., Demirkol Canli S., Kucukkaraduman B., TÜRK C., Sahin O., GÜRE A. O.
JOURNAL OF CANCER, cilt.11, sa.4, ss.949-961, 2020 (SCI-Expanded)

XVI. **Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes**
Gulluoglu S., Tuysuz E. C., Sahin M., Kuskucu A., Yaltirik C. K., Ture U., Kucukkaraduman B., Akbar M. W., GÜRE A. O., Bayrak O. F., et al.
BRAIN RESEARCH, cilt.1700, ss.199-210, 2018 (SCI-Expanded)

XVII. **Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer**
Taskoparan B., Seza E. G., Demirkol S., Tuncer S., Stefek M., Gure A. O., BANERJEE S.
CELLULAR ONCOLOGY, cilt.40, sa.6, ss.563-578, 2017 (SCI-Expanded)

XVIII. **MicroRNA expression patterns in canine mammary cancer show significant differences between metastatic and non-metastatic tumours**
Bulkowska M., Rybicka A., Senses K. M., Ulewicz K., Witt K., Szymanska J., Taciak B., Klopfleisch R., Hellmen E., Dolka I., et al.
BMC CANCER, cilt.17, 2017 (SCI-Expanded)

XIX. **TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT**
Hill R., Madureira P. A., Ferreira B., Baptista I., Machado S., Colaco L., dos Santos M., Liu N., Dopazo A., Ugurel S., et al.
NATURE COMMUNICATIONS, cilt.8, 2017 (SCI-Expanded)

XX. **Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma**
Senses K. M., Ghasemi M., Akbar M. W., Isbilen M., Fallacara A. L., Frankenburg S., Schenone S., Lotem M., Botta M., GÜRE A. O.
MEDCHEMCOMM, cilt.8, sa.1, ss.88-95, 2017 (SCI-Expanded)

XXI. **A Combined ULBP2 and SEMA5A Expression Signature as a Prognostic and Predictive Biomarker for Colon Cancer**
Demirkol S., Gomceli I., Isbilen M., Dayanc B. E., Tez M., Bostanci E. B., Turhan N., Akoglu M., Ozyerli E., Durdu S., et al.
JOURNAL OF CANCER, cilt.8, sa.7, ss.1113-1122, 2017 (SCI-Expanded)

XXII. **Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade**
Lotem M., Merims S., Frank S., Hamburger T., Nissan A., Kadouri L., Cohen J., Straussman R., Eisenberg G., Frankenburg S., et al.

JOURNAL OF IMMUNOLOGY RESEARCH, cilt.2016, 2016 (SCI-Expanded)

XXIII. **Colon Cancer Associated Transcript-1 (CCAT1) Expression in Adenocarcinoma of the Stomach**
Mizrahi I., Mazeh H., Grinbaum R., Beglaibter N., Wilschanski M., Pavlov V., Adileh M., Stojadinovic A., Avital I., Gure A. O., et al.
JOURNAL OF CANCER, cilt.6, sa.2, ss.105-110, 2015 (SCI-Expanded)

XXIV. **Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-PNA molecular beacons**
Kam Y., Rubinstein A., Naik S., Djavsarov I., Halle D., Ariel I., Gure A. O., Stojadinovic A., Pan H., Tsivin V., et al.
CANCER LETTERS, cilt.352, sa.1, ss.90-96, 2014 (SCI-Expanded)

XXV. **Epigenetic Mechanisms Underlying the Dynamic Expression of Cancer-Testis Genes, PAGE2, -2B and SPANX-B, during Mesenchymal-to-Epithelial Transition**
Yilmaz-Ozcan S., SADE MEMİŞOĞLU A., Kucukkaraduman B., Kaygusuz Y., Senses K. M., BANERJEE S., GÜRE A. O.
PLOS ONE, cilt.9, sa.9, 2014 (SCI-Expanded)

XXVI. **Mitochondrial carrier homolog 1 (Mtch1) antibodies in neuro-Behcet's disease**
VURAL B., Sehitoglu E., Cavus F., Yalcinkaya N., Haytural H., Kucukerden M., ULUSOY C. A., Ugurel E., Turan S., Bulut L., et al.
JOURNAL OF NEUROIMMUNOLOGY, cilt.263, sa.1-2, ss.139-144, 2013 (SCI-Expanded)

XXVII. **Cancer-testis gene expression is associated with the methylenetetrahydrofolate reductase 677 C > T polymorphism in non-small cell lung carcinoma**
Senses K. M., Gonen M., Barutcu A. R., KALAYLIOĞLU AKYILDIZ Z. I., Isbilen M., Konu O., Chen Y. T., Altorki N. K., Gure A. O.
BMC MEDICAL GENETICS, cilt.14, 2013 (SCI-Expanded)

XXVIII. **Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence**
Alaiyan B., Ilyayev N., Stojadinovic A., Izadjoo M., Roistacher M., Pavlov V., Tzivin V., Halle D., Pan H., Trink B., et al.
BMC CANCER, cilt.13, 2013 (SCI-Expanded)

XXIX. **Predicting chemotherapy sensitivity profiles for breast cancer cell lines with and without stem cell-like features**
Isbilen M., Senses K. M., Gure A. O.
Current Signal Transduction Therapy, cilt.8, sa.3, ss.268-273, 2013 (SCI-Expanded)

XXX. **Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA**
Dayanc B. E., Bansal S., Gure A. O., Gollnick S. O., Repasky E. A.
INTERNATIONAL JOURNAL OF HYPERTHERMIA, cilt.29, sa.5, ss.480-490, 2013 (SCI-Expanded)

XXXI. **Colon cancer associated transcript-1: A novel RNA expressed in malignant and pre-malignant human tissues**
Nissan A., Stojadinovic A., Mitrani-Rosenbaum S., Halle D., Grinbaum R., Roistacher M., Bochem A., Dayanc B. E., Ritter G., Gomceli I., et al.
INTERNATIONAL JOURNAL OF CANCER, cilt.130, sa.7, ss.1598-1606, 2012 (SCI-Expanded)

XXXII. **Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease.**
VURAL B., Ugurel E., TÜZÜN E., KÜRTÜNCÜ M., Zuliani L., Cavus F., İÇÖZ S., ERDAĞ E., GÜL A., GÜRE A. O., et al.
Journal of neuroimmunology, cilt.239, sa.1-2, ss.91-7, 2011 (SCI-Expanded)

XXXIII. **Seroreactivity against PTEN-induced putative kinase 1 (PINK1) in Turkish patients with Behçet's disease.**
VURAL B., Demirkan A., Ugurel E., Kalaylioglu-Wheeler Z., Esen B. A., Gure A. O., Gül A., Ozbek U.
Clinical and experimental rheumatology, cilt.27, sa.2 Suppl 53, 2009 (SCI-Expanded)

XXXIV. **SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome**
Sabater L., Titulaer M., Saiz A., Verschuuren J., Guere A. O., Graus F.
NEUROLOGY, cilt.70, sa.12, ss.924-928, 2008 (SCI-Expanded)

XXXV. **Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy**

Spisek R., Kukreja A., Chen L., Matthews P., Mazumder A., Vesole D., Jagannath S., Zebroski H. A., Simpson A. J. G., Ritter G., et al.
JOURNAL OF EXPERIMENTAL MEDICINE, cilt.204, sa.4, ss.831-840, 2007 (SCI-Expanded)

XXXVI. **NY-BR-1 is a differentiation antigen of the mammary gland**
Jäger D., Filonenko V., Gout I., Frosina D., Eastlake-Wade S., Castelli S., Varga Z., Moch H., Chen Y., Busam K. J., et al.
Applied Immunohistochemistry and Molecular Morphology, cilt.15, sa.1, ss.77-83, 2007 (SCI-Expanded)

XXXVII. **NY-ESO-1: Review of an immunogenic tumor antigen**
Gnjatic S., Nishikawa H., Jungbluth A. A., Guere A. O., Ritter G., Jaeger E., Chen Y., Old L. J.
ADVANCES IN CANCER RESEARCH, VOL 95, cilt.95, ss.1-30, 2006 (SCI-Expanded)

XXXVIII. **Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer**
Gure A. O., Chua R., Williamson B., Gonen M., Ferreira C., Gnjatic S., Ritter G., Simpson A., Chen Y., Old L., et al.
CLINICAL CANCER RESEARCH, cilt.11, sa.22, ss.8055-8062, 2005 (SCI-Expanded)

XXXIX. **Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters**
VURAL B., Chen L., Saip P., Chen Y., Ustuner Z., Gonen M., Simpson A. J. G., Old L. J., Ozbek U., Gure A. O.
Cancer, cilt.103, sa.12, ss.2575-2583, 2005 (SCI-Expanded)

XL. **Identification of cancer/testis-antigen genes by massively parallel signature sequencing**
Chen Y., Scanlan M., Venditti C., Chua R., Theiler G., Stevenson B., Iseli C., Gure A. O., Vasicek T., Strausberg R., et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, cilt.102, sa.22, ss.7940-7945, 2005 (SCI-Expanded)

XLI. **Identification and characterization of mouse SSX genes: a multigene family on the X chromosome with restricted cancer/testis expression**
Chen Y., Alpen B., Ono T., Gure A. O., Scanlan M., Biggs W., Arden K., Nakayama E., Old L.
GENOMICS, cilt.82, sa.6, ss.628-636, 2003 (SCI-Expanded)

XLII. **The SSX gene family: Characterization of 9 complete genes**
Gure A. O., Wei I., Old L., Chen Y.
INTERNATIONAL JOURNAL OF CANCER, cilt.101, sa.5, ss.448-453, 2002 (SCI-Expanded)

XLIII. **Cancer/testis antigens: an expanding family of targets for cancer immunotherapy**
Scanlan M., Gure A. O., Jungbluth A., Old L., Chen Y.
IMMUNOLOGICAL REVIEWS, cilt.188, ss.22-32, 2002 (SCI-Expanded)

XLIV. **A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved**
Alpen B., Gure A. O., Scanlan M., Old L., Chen Y.
GENE, cilt.297, ss.141-149, 2002 (SCI-Expanded)

XLV. **Cancer-related serological recognition of human colon cancer: Identification of potential diagnostic and immunotherapeutic targets**
Scanlan M. J., Welt S., Gordon C. M., Chen Y., Gure A. O., Stockert E., Jungbluth A. A., Ritter G., Jäger D., Jäger E., et al.
Cancer Research, cilt.62, sa.14, ss.4041-4047, 2002 (SCI-Expanded)

XLVI. **Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library**
Jäger D., Stockert E., Güre A. O., Scanlan M. J., Karbach J., Jäger E., Knuth A., Old L. J., Chen Y.
Cancer Research, cilt.61, sa.5, ss.2055-2061, 2001 (SCI-Expanded)

XLVII. **Serological cloning of a melanocyte rab guanosine 5'-triphosphate- binding protein and a chromosome condensation protein from a melanoma complementary DNA library**
Jäger D., Stockert E., Jäger E., Güre A. O., Scanlan M. J., Knuth A., Old L. J., Chen Y.
Cancer Research, cilt.60, sa.13, ss.3584-3591, 2000 (SCI-Expanded)

XLVIII. **Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer**
Gure A. O., Stockert E., Scanlan M., Keresztes R., Jager D., Altorki N., Old L., Chen Y.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, cilt.97, sa.8,

ss.4198-4203, 2000 (SCI-Expanded)

XLIX. **Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9**
Scanlan M., Altorki N., Gure A. O., Williamson B., Jungbluth A., Chen Y., Old L.
CANCER LETTERS, cilt.150, sa.2, ss.155-164, 2000 (SCI-Expanded)

L. **CT10: A new cancer-testis (CT) antigen homologous to CT7 and the mage family, identified by representational-difference analysis**
Güre A. O., Stockert E., Arden K. C., Boyer A. D., Viars C. S., Scanlan M. J., Old L. J., Chen Y.
International Journal of Cancer, cilt.85, sa.5, ss.726-732, 2000 (SCI-Expanded)

LI. **Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: Characterization of tissue-specific ING1 transcripts and a homologue gene**
Jäger D., Stockert E., Scanlan M. J., Güre A. O., Jäger E., Knuth A., Old L. J., Chen Y.
Cancer Research, cilt.59, sa.24, ss.6197-6204, 1999 (SCI-Expanded)

LII. **Antigens recognized by autologous antibody in patients with renal-cell carcinoma**
Scanlan M. J., Gordan J. D., Williamson B., Stockert E., Bander N. H., Jongeneel V., Gure A. O., Jäger D., Jäger E., Knuth A., et al.
International Journal of Cancer, cilt.83, sa.4, ss.456-464, 1999 (SCI-Expanded)

LIII. **Isoforms of the human PDZ-73 protein exhibit differential tissue expression**
Scanlan M., Williamson B., Jungbluth A., Stockert E., Arden K., Viars C., Gure A. O., Gordan J., Chen Y., Old L.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, cilt.1445, sa.1, ss.39-52, 1999 (SCI-Expanded)

LIV. **Expression of SSX genes in human tumors**
Türeci Ö., Chen Y., Sahin U., Güre A. O., Zwick C., Villena C., Tsang S., Seitz G., Old L. J., Pfreundschuh M.
International Journal of Cancer, cilt.77, sa.1, ss.19-23, 1998 (SCI-Expanded)

LV. **Characterization of human colon cancer antigens recognized by autologous antibodies**
Scanlan M. J., Chen Y., Williamson B., Gure A. O., Stockert E., Gordan J. D., Türeci Ö., Sahin U., Pfrendschuh M., Old L. J.
International Journal of Cancer, cilt.76, sa.5, ss.652-658, 1998 (SCI-Expanded)

LVI. **Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library**
Chen Y., Gure A. O., Tsang S., Stockert E., Jager E., Knuth A., Old L.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, cilt.95, sa.12, ss.6919-6923, 1998 (SCI-Expanded)

LVII. **Human lung cancer antigens recognized by autologous antibodies: Definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3**
Güre A. O., Altorki N. K., Stockert E., Scanlan M. J., Old L. J., Chen Y.
Cancer Research, cilt.58, sa.5, ss.1034-1041, 1998 (SCI-Expanded)

LVIII. **SSX: A multigene family with several members transcribed in normal testis and human cancer**
Gure A. O., Türeci Ö., Sahin U., Tsang S., Scanlan M. J., Jäger E., Knuth A., Pfreundschuh M., Old L. J., Chen Y.
International Journal of Cancer, cilt.72, sa.6, ss.965-971, 1997 (SCI-Expanded)

LIX. **A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening**
Chen Y., Scanlan M., Sahin U., Tureci O., Gure A. O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., Old L.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, cilt.94, sa.5, ss.1914-1918, 1997 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

I. **Dominant B-cell epitopes from cancer/stem cell antigen SOX2 recognized by serum samples from cancer patients.**
Shih J., Rahman M., Luong Q. T., Lomeli S. H., Riss J., Prins R. M., Gure A. O., Zeng G.

American journal of clinical and experimental immunology, cilt.3, sa.2, ss.84-90, 2014 (Hakemli Dergi)

II. **Autologous anti-SOX2 antibody responses reflect intensity but not frequency of antigen expression in small cell lung cancer**
Atakan S., Bayiz H., SAK S., Poyraz A., VURAL B., Yildirim A. S., Demirag F., GÜRE A. O.
BMC CLINICAL PATHOLOGY, cilt.14, 2014 (ESCI)

III. **Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2**
Zhuang R., Zhu Y., Fang L., Liu X., Tian Y., Chen L., Ouyang W., Xu X., Jian J., Güre A. O., et al.
Cancer Immunity, cilt.6, 2006 (Scopus)

IV. **Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein**
Chen Y., Venditti C. A., Theiler G., Stevenson B. J., Iseli C., Gure A. O., Jongeneel C. V., Old L. J., Simpson A. J. G.
Cancer Immunity, cilt.5, 2005 (Scopus)

V. **Serological analysis of expression cDNA libraries (SEREX): an immunoscreening technique for identifying immunogenic tumor antigens.**
Chen Y., Gure A. O., Scanlan M. J.
Methods in molecular medicine, cilt.103, ss.207-216, 2005 (Scopus)

VI. **SSX antigens as tumor vaccine targets in human sarcoma**
Ayyoub M., Brehm M., Metthez G., Talbot S., Dutoit V., Taub R. N., Keohan M., Gure A. O., Chen Y., Williamson B., et al.
Cancer Immunity, cilt.3, ss.1-8, 2003 (Scopus)

VII. **Humoral immunity to human breast cancer: Antigen definition and quantitative analysis of mRNA expression**
Scanlan M. J., Gout I., Gordon C. M., Williamson B., Stockert E., Gure A. O., Jäger D., Chen Y., Mackay A., O'Hare M. J., et al.
Cancer Immunity, cilt.1, ss.1-17, 2001 (Scopus)

Metrikler

Yayın: 66
Atıf (WoS): 5588
Atıf (Scopus): 6471
H-İndeks (WoS): 29
H-İndeks (Scopus): 31